Effective Second-Line Treatment with Cetuximab and Bevacizumab in a Patient with Hepatic Metastases of Colorectal Cancer and Hyperbilirubinemia

Publisher： Karger

E-ISSN： 2296-5262|30|10|509-512

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.10, 2007-09, pp. : 509-512

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Feasibility of Using Cetuximab and Bevacizumab in a Patient with Colorectal Cancer and Terminal Renal Failure

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 209-210

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Irinotecan in Second-Line Therapy of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 15-17

Karger

Access to resources Recommend Favorite

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

By  

Oncology, Vol. 83, Iss. 2, 2012-07 ,pp. : 101-107

Karger

Access to resources Recommend Favorite